Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-2-MOG fusion protein
- Development stage
- Preclinical
- Lead developer
- Amgen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
IL-2-MOG fusion protein is a recombinant fusion protein consisting of interleukin-2 (IL-2) fused to myelin oligodendrocyte glycoprotein (MOG) peptide (specifically MOG35-55). Developed by Amgen, this therapeutic candidate is designed to treat autoimmune diseases, specifically multiple sclerosis (or its animal model, experimental autoimmune encephalomyelitis [EAE]). The IL-2 portion of the fusion protein selectively binds to the high-affinity interleukin-2 receptor (IL-2R, particularly CD25) on regulatory T cells (Tregs), targeting the MOG antigen to these cells. The Tregs then internalize, process, and present the MOG antigen via MHC class II molecules to MOG-specific conventional T cells. This antigen presentation by Tregs acts tolerogenically, converting pathogenic MOG-specific T cells into Tregs and suppressing autoimmunity, thereby ameliorating EAE.
- Other names
- IL-2-MOGIL2-MOGIL 2-MOGTreg-specific IL-2-MOG fusion protein
02
Targets
ALB (Human serum albumin)IL-2RA (Interleukin-2 receptor subunit alpha)IL2RB (IL-2 receptor beta chain)MOG (Myelin oligodendrocyte glycoprotein)
Beyond the preview
Go deeper on IL-2-MOG fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-2-MOG fusion protein.